David Fajgenbaum

To make the most of it. Leverage that. Exactly. And so let's think about how this relates back to the work that you're doing. I mean, we've got systems that are broken that you guys are working to address. How do you try to leverage what, maybe what's already in place? I don't know. Or maybe you just try to start from scratch. How do you think about? You know, I think for us, we were working, you know, I'm from El Salvador. We were working in some of the countries that had the highest rates of violence about 20 years ago when we started working.

Olen todella iloinen kuulemasta siitä. Kiitos. Kuten sanoit aiemmin, se on kaikki vaikuttavaa vaikutusta. Siksi teemme sitä, mitä teemme. Teidän vaikutuksenne on niin ympäristöinen ja myös niin syvällä ympäristössä.

We have a very bold and broad mission, and that's to save and improve lives with the drugs we already have by repurposing medicines. We're called EveryCure, which is a big, broad remit. But I'll share with you about one patient in particular named Joseph, and actually he was at the TED Talk that I gave just a few months ago and was able to be there in the audience, which was so special, because I told his story during the talk, and his story is that

Hän oli kriittisesti syövällä rauhallisella rauhallisuudella nimeltä Poem-syndroomissa ja hänen lääkäränsä yritti kaikkea, mitä lääkärit yrittivät yrittää rauhallisella rauhallisuudella. Hänen ystävänsä, Tara, liittyi minun joukkoon viikonloppuun. Joseph oli saavuttamassa lääkärin koulutuksessa viikonloppuun, koska mikään ei toiminut.

I was able to get in touch with his doctor on that Saturday and recommend three drugs that were made for multiple myeloma, which is a cancer that's similar to poem syndrome, but those drugs are not used for poems. The doctor and I had a long discussion and there were a lot of debates about whether he could tolerate these medicines and whether we should give this last Hail Mary effort. The doctor decided to try the medicines and amazingly Joseph responded incredibly well about

Tänä päivänä hän oli uudestaan uudestaan uudestaan uudestaan uudestaan uudestaan uudestaan.

jollain tapauksessa jollain tapauksessa jollain tapauksessa jollain tapauksessa jollain tapauksessa jollain tapauksessa jollain tapauksessa jollain tapauksessa jollain tapauksessa

On useita tapauksia, joissa emme pysty löytämään repurpoosituotantoa asiakkaalle, ja he joutuvat pysymään huoneeseen. Se on todella huomattavaa. Kun on yksittäinen tehtävä, kuten meillä on, ja se on se, mitä me pystymme miettimään, ja se on se, mikä meidät vaikuttaa. Olen käynyt erilaisia kokemuksia ja olen ollut toisella puolella.

It's heartbreaking when you're not able to find the solution. It's also really motivating. It just pushes us to work harder and harder. And then there's patients like Joseph and others that we've been able to help and save that motivates us even further. It's the setbacks, the cases where we're not able to help patients, and then also the patients where we are able to help patients. It's really created a circuit. And anytime I'm struggling to

you know, with the challenges of this nonprofit, of every cure and the work that we do in research, I just think about what these patients are going through, which just, you know, what we're doing pales in comparison to the suffering that they're going through. And just, we're just trying to stay as motivated as we can to find solutions. What about you? How do you get through these challenges and these setbacks? Yeah, I mean, it's hard, right? I mean, I just got a text yesterday from someone, a nurse at a clinic that we've been working in the schools. We work in public schools in different parts of

Se, mitä näet, on melkein kuin jatkuvan painon jälkeen. Jatkuvan painon jälkeen, kuten meidän tapauksessamme, jatkuvan painon jälkeen, jatkuvan painon jälkeen.

Pohjimmilta näkökulmista, joissa voit auttaa. Kuulostaa, että menet samanlaiseen asiaan. Mitä ajattelet tasapainosta? Olet aloittanut hyperlokalaisena ja kasvanut tasapainossa. Mitä ajattelet tasapainon vaikutuksesta?

Yksityiskohtaiset työntekijät ovat erittäin suuri resurssi. Näen yksityiskohtaisuuksia työskentelyssämme. Se alkoi hyvin hyperlokalisti minun kanssa, koska olin todella syköinen ja löysin drugin, jonka repurpoosin itselleen. Silloin aloitin miettimään, että jos tämä drugi toimii minulle, onko muissa drogoissa, jotka voivat toimia muille henkilöille?

First it was just Castleman's patients, and then we started looking at diseases related to Castleman's, other rare diseases. We've now repurposed 14 drugs for diseases they weren't intended for, and now thousands of patients are alive because of these drugs that weren't made for their disease. But about three years ago, we decided to really scale things, and that was with the creation of this nonprofit, EveryCure. And it really coincided with the emergence of artificial intelligence. So, you know, I run a lab at the University of Pennsylvania, and our lab

Olen erittäin ylpeä teemme kanssa. Voimme tutkia muutamia drogeja muutaman vuoden aikana ja tehdä paljon edistämistä. Olemme todella ylpeä siitä. Mutta sitten kun ajattelee, mitä taiteellinen tieto voi tehdä, jotta voidaan kuvailla maailman tietoa kaikkien drogeiden ja kaikkien ongelmien kautta, melkein nopeasti.

To come up with predictions on how likely drugs are to work in new diseases. It's really mind-boggling. I'd just like to put some numbers around it. When we built our first AI platform about two and a half years ago and ran it for the first time, it took us 100 days to compute 75 million scores. Because there's 4,000 drugs and there's 18,000 diseases. If you tried every drug for every disease...

It would be 75 million possibilities. It took 100 days. Now it takes about 17 hours to compute the same 75 million scores. The scores are really accurate. They're telling us that drugs like lidocaine can help potential patients with breast cancer. Things that our brains would have never just gone to immediately. But what's so interesting also is that a lot of these insights are based on research that

Me ihmiset olemme jo tehneet sitä. Olemme tutkineet tämän lääkärin lääkärin lääkärin lääkärin lääkärin lääkärin lääkärin lääkärin lääkärin lääkärin lääkärin

It's really up to us. Like you, we won an Audacious Project award this past year. Now it's up to us to leverage the power of artificial intelligence to look across 75 million possibilities. But then for us humans to say, this drug for this disease really needs to be studied in the lab, this one needs to be studied in clinical trials, and this one we have to get to patients. One of those diseases...

Olen puhunut tuosta keskustelusta keskustelusta, jonka käsitin kesässä. Se on lukavurin. Se on kehittynyt kemo- terapian muodostamisen jälkeen. Se on käytetty kemo- terapian muodostamisen jälkeen.